CoChat

An iridium( iii )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

This is the first report of a metal complex that targets the BRD4-acylated histone protein-protein interaction (PPI).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/c5sc02321a

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Chemical structures of the cyclometallated Ir(iii) and Rh(iii) complexes (racemates) used for preliminary screening. Only one enantiomer is shown for clarity; complexes 1 and 17 are OTf salts, and others are PF6 salts.
Fig. 1 Chemical structures of the cyclometallated Ir(iii) and Rh(iii) complexes (racemates) used for preliminary screening. Only one enantiomer is shown for clarity; complexes 1 and 17 are OTf salts, and others are PF6 salts.CC BY-NC · PubMed Central
Fig. 2 Displacement of a tetra-acetylated H4 peptide from BRD4 by a selection of Ir(iii)/Rh(iii) complexes at 100 μM in a TR-FRET assay. Error bars represent the standard deviations of the results from three independent experiments.
Fig. 2 Displacement of a tetra-acetylated H4 peptide from BRD4 by a selection of Ir(iii)/Rh(iii) complexes at 100 μM in a TR-FRET assay. Error bars represent the standard deviations of the results from three independent experiments.CC BY-NC · PubMed Central
Fig. 3 (a) Chemical structures of the cyclometallated Ir(iii) and Rh(iii) complexes (racemates) used for structure-activity analysis (SAR). (b) Displacement of a tetra-acetylated H4 peptide from BRD4 by complex 1 and analogues 1a–1j at 10 μM in a TR-FRET assay. Error bars represent the standard deviations of the results from three independent experiments.
Fig. 3 (a) Chemical structures of the cyclometallated Ir(iii) and Rh(iii) complexes (racemates) used for structure-activity analysis (SAR). (b) Displacement of a tetra-acetylated H4 peptide from BRD4 by complex 1 and analogues 1a–1j at 10 μM in a TR-FRET assay. Error bars represent the standard deviations of the results from three independent experiments.CC BY-NC · PubMed Central
Fig. 4 Ability of 1a to displace H4AcK4 peptide from (a) BRD4(1) and (b) BRD4(2) in a time-resolved-fluorescent resonance electron transfer (TR-FRET) assay. Binding of H4AcK4 to BRD4(1) was strongly inhibited by 1a, with half-maximum inhibitory concentration (IC50) value of 0.07 μM. Error bars represent the standard deviations of the results from three independent experiments. LC-MS/MS analysis of (c) BRD4(1), (d) BRD4(1) with 1a and (e) 1a only. BRD4(1) and 1a complex were buffered in 10 mM Tris–HCl, pH = 7.5, 500 mM NaCl and incubated at 25 °C for 2 h. The sample was analyzed by positive ion mass spectra.
Fig. 4 Ability of 1a to displace H4AcK4 peptide from (a) BRD4(1) and (b) BRD4(2) in a time-resolved-fluorescent resonance electron transfer (TR-FRET) assay. Binding of H4AcK4 to BRD4(1) was strongly inhibited by 1a, with half-maximum inhibitory concentration (IC50) value of 0.07 μM. Error bars represent the standard deviations of the results from three independent experiments. LC-MS/MS analysis of (c) BRD4(1), (d) BRD4(1) with 1a and (e) 1a only. BRD4(1) and 1a complex were buffered in 10 mM Tris–HCl, pH = 7.5, 500 mM NaCl and incubated at 25 °C for 2 h. The sample was analyzed by positive ion mass spectra.CC BY-NC · PubMed Central
Fig. 5 Chromatin immunoprecipitation (ChIP) analysis showed that 1a selectively decreased the binding of BRD4 to MYC, Bcl-2 and CDK6, but not housekeeping genes (B2M) in (a) A375 and (b) A2058 cells. Bar graphs represented the mean enrichment relative to input and error bars reflect standard deviation of results derived from biological triplicate experiments. Significantly different at ***p < 0.01. Error bars represent the standard deviations of the results from three independent experiments.
Fig. 5 Chromatin immunoprecipitation (ChIP) analysis showed that 1a selectively decreased the binding of BRD4 to MYC, Bcl-2 and CDK6, but not housekeeping genes (B2M) in (a) A375 and (b) A2058 cells. Bar graphs represented the mean enrichment relative to input and error bars reflect standard deviation of results derived from biological triplicate experiments. Significantly different at ***p < 0.01. Error bars represent the standard deviations of the results from three independent experiments.CC BY-NC · PubMed Central
Fig. 6 Immunoblotting analysis of the effect of 1a and (+)-JQ1 treatment in (a) A375 and (b) A2058 cells. Densitometry analysis revealed that 1a inhibited c-myc, Bcl-2, ERK 1/2, p-ERK 1/2 and PARP expression. Dose response analysis of cell viability of complex 1a against (c) A375 cells and (d) A2058 cells. Error bars represent the standard deviations of the results from three independent experiments. Normalized proliferation curves in the colony formation assay for (e) A375 and (f) A2058 cells treated with vehicle or 1a (0.001–10 μM) measured by crystal violet staining. Error bars represent the standard deviations of the results from three independent experiments. (g) The relationship between the IC50 of the binding ability of BRD4(1)/peptide and the log of IC50 of A375 cell viability, and a trend of positive correlation was observed (r = 0.8207, n = 14).
Fig. 6 Immunoblotting analysis of the effect of 1a and (+)-JQ1 treatment in (a) A375 and (b) A2058 cells. Densitometry analysis revealed that 1a inhibited c-myc, Bcl-2, ERK 1/2, p-ERK 1/2 and PARP expression. Dose response analysis of cell viability of complex 1a against (c) A375 cells and (d) A2058 cells. Error bars represent the standard deviations of the results from three independent experiments. Normalized proliferation curves in the colony formation assay for (e) A375 and (f) A2058 cells treated with vehicle or 1a (0.001–10 μM) measured by crystal violet staining. Error bars represent the standard deviations of the results from three independent experiments. (g) The relationship between the IC50 of the binding ability of BRD4(1)/peptide and the log of IC50 of A375 cell viability, and a trend of positive correlation was observed (r = 0.8207, n = 14).CC BY-NC · PubMed Central
Fig. 7 Anti-proliferative activity of 1a in an in vivo xenograft model of melanoma. (a) Photographs of dissected tumors from the control (vehicle) and treatment (1a, 100 mg kg–1). (b) Average A375 tumour volume in the control group and treatment group (1a, 100 mg kg–1). Each group contained six mice and results are reported as the values of the mean ± SEM. (c) Tumour inhibition of A375 xenografts in the treatment group (1a, 100 mg kg–1) expressed as percentage reduction in tumor volume compared to the control group. The results were analyzed using the Student's t-test. Significantly different at 0.01 < **p < 0.05. (d) Average tumor weight of the vehicle control group versus the treatment group (1a, 100 mg kg–1). (e) Average body weight of the two groups. Each group contained six mice, and results were reported as the values of the mean ± SEM. The results were analyzed using the Student's t-test. Significantly different at 0.01 < **p < 0.05. (f) Heat map of regulated genes of the ECM pathway and VEGF signaling pathway following treatment with 1a. The color scale in the inset represents the log-fold change of expression compared with untreated control.
Fig. 7 Anti-proliferative activity of 1a in an in vivo xenograft model of melanoma. (a) Photographs of dissected tumors from the control (vehicle) and treatment (1a, 100 mg kg–1). (b) Average A375 tumour volume in the control group and treatment group (1a, 100 mg kg–1). Each group contained six mice and results are reported as the values of the mean ± SEM. (c) Tumour inhibition of A375 xenografts in the treatment group (1a, 100 mg kg–1) expressed as percentage reduction in tumor volume compared to the control group. The results were analyzed using the Student's t-test. Significantly different at 0.01 < **p < 0.05. (d) Average tumor weight of the vehicle control group versus the treatment group (1a, 100 mg kg–1). (e) Average body weight of the two groups. Each group contained six mice, and results were reported as the values of the mean ± SEM. The results were analyzed using the Student's t-test. Significantly different at 0.01 < **p < 0.05. (f) Heat map of regulated genes of the ECM pathway and VEGF signaling pathway following treatment with 1a. The color scale in the inset represents the log-fold change of expression compared with untreated control.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 3

  1. Florence, 2001, Front. Biosci., 6, d1008
  2. Chung, 2012, Drug Discovery Today: Ther. Strategies, 9, e111
  3. Chen, 2014, BioMed Res. Int., 2014, 232870

Cited by

See all 144

Metadata

Authors
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H.
Affiliations
  • University of Macau (MO)
  • Hong Kong Baptist University (HK)
  • Chinese Academy of Sciences (CN)
  • Hong Kong Polytechnic University (HK)
  • Department of Fragrance and Cosmetic Science
Corresponding author
  • Ma, Dik-Lung
  • Cai, Zongwei
  • Leung, Chung-Hang
Venue
Chemical Science
Published
2015
Volume
6
Issue
10
Pages
5400-5408
ISSN
  • 2041-6520 (ISSN-L)
  • 2041-6539
OpenAlex
W4247705075
Cited by
138
References
59
Citations by year
2026: 4 · 2025: 9 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 15 · 2019: 11 · 2018: 12 · 2017: 30 · 2016: 27 · 2015: 4
FWCI
10.72
Type
journal article
Language
en
Open access
Locations
  • Chemical Science (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HKBU Institutional Repository (Hong Kong Baptist University) (submittedVersion, other-oa)
  • PolyU Institutional Research Archive (Hong Kong Polytechnic University) (submittedVersion)
Funders
  • Hong Kong Baptist University (FRG2/14-15/004)
  • Health and Medical Research Fund (HMRF/13121482, HMRF/14130522)
  • Science and Technology Development Fund (103/2012/A3, 098/2014/A2)
  • Universidade de Macau (MYRG091(Y3-L2)-ICMS12-LCH, MYRG2015-00137-ICMS-QRCM, MRG023/LCH/2013/ICMS)
  • The Research Grants Council, University Grants Committee, Hong Kong (HKBU/201811, HKBU/204612, HKBU/201913)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
iridium(III) complexes, BRD4, protein-protein interaction inhibitors, epigenetic inhibitors, anticancer agents, melanoma, metal-based anticancer agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An iridium( iii )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent. https://app.cochat.ai/papers/10.1039/c5sc02321a
The paper
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015). An iridium( iii )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent. Chemical Science. https://doi.org/10.1039/c5sc02321a

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.